Screening for Latent Polycythemia Vera in Renal Cell Carcinoma–Associated Erythrocytosis
Main Article Content
Keywords
erythrocytosis, molecular diagnostics, polycythemia vera, renal cell carcinoma
Abstract
N/A
References
1. Mithoowani S, Laureano M, Crowther MA, Hillis CM. Investigation and management of erythrocytosis. Can Med Assoc J. 2020 Aug;192(32):E913–18. 10.1503/cmaj.191587
2. McMullin MF, Harrison CN, Ali S, Cargo C, Chen F, Ewing J, et al. A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline. Br J Haematol. 2019 Jan;184(2):176–91. 10.1111/bjh.15648
3. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005 Mar;365(9464):1054–61. 10.1016/S0140-6736(05)71142-9
4. Jalowiec KA, Vrotniakaite-Bajerciene K, Jalowiec J, Frey N, Capraru A, Wojtovicova T, et al. JAK2 unmutated polycythaemia–real-world data of 10 years from a tertiary reference hospital. J Clinical Med. 2022 Jun;11(12):3393. 10.3390/jcm11123393
5. Namdaro-lu S, Tekgündüz E, Altuntaş F. Coexistence of essential thrombocythemia, iron-refractory iron deficiency anaemia and renal cell carcinoma. Hematol Rep. 2016 Mar;8(1):6235. 10.4081/hr.2016.6235
6. Zhao J, Moch H. Absence of JH2 domain mutations of the tyrosine kinase JAK2 in renal cell carcinomas. Acta Oncol. 2008;47(3):474–6. 10.1080/02841860701499390
2. McMullin MF, Harrison CN, Ali S, Cargo C, Chen F, Ewing J, et al. A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline. Br J Haematol. 2019 Jan;184(2):176–91. 10.1111/bjh.15648
3. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005 Mar;365(9464):1054–61. 10.1016/S0140-6736(05)71142-9
4. Jalowiec KA, Vrotniakaite-Bajerciene K, Jalowiec J, Frey N, Capraru A, Wojtovicova T, et al. JAK2 unmutated polycythaemia–real-world data of 10 years from a tertiary reference hospital. J Clinical Med. 2022 Jun;11(12):3393. 10.3390/jcm11123393
5. Namdaro-lu S, Tekgündüz E, Altuntaş F. Coexistence of essential thrombocythemia, iron-refractory iron deficiency anaemia and renal cell carcinoma. Hematol Rep. 2016 Mar;8(1):6235. 10.4081/hr.2016.6235
6. Zhao J, Moch H. Absence of JH2 domain mutations of the tyrosine kinase JAK2 in renal cell carcinomas. Acta Oncol. 2008;47(3):474–6. 10.1080/02841860701499390
Article Sidebar
Published
Apr 22, 2023
Article Details
How to Cite
Screening for Latent Polycythemia Vera in Renal Cell Carcinoma–Associated Erythrocytosis. (2023). Journal of Kidney Cancer, 10(1), 26-27. https://doi.org/10.15586/jkcvhl.v10i1.276
Section
Letter to Editor
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
How to Cite
Screening for Latent Polycythemia Vera in Renal Cell Carcinoma–Associated Erythrocytosis. (2023). Journal of Kidney Cancer, 10(1), 26-27. https://doi.org/10.15586/jkcvhl.v10i1.276